biologic

Adacel

Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed

Loss of exclusivityJune 2017projected — 12-year biologic exclusivity estimate
CompanySanofi Vaccines Canada Ltd.

Drug detail

Brand nameAdacel
Active ingredientTetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed
Strength0.5ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalJune 2005
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Adacel patent cliff — loss of exclusivity June 2017 | CliffBio